|B;Gv~ Q)D)p,P qLnMW

T|F% )n)z

Aung Naing¹, Xinjun Liang², Sarwan Bishnoi³, Jie Li⁴, Sanjeev Deva⁵,
Funan Liu⁶, John Park⁷, Dan Feng⁸, Victoria Chang⁹, Cunjing Yu¹⁰,
1@w{[ {5Y⁹F G_x#d_[ |)eS(⁹i =g5 @@tD¹⁰K Zxh]R= |SZYd?O¹¹9 nT3@c] $pF(¹²

¹ The University of Texas – MD Anderson Cancer Center, Houston, TX, USA
² Hubei Cancer Hospital, Wuhan, Hubei, China
³ Ashford Cancer Centre Research, Glandore, SA, Australia
⁴ Jining First People’s Hospital, Jining, Shandong, China
⁵ Auckland City Hospital, Auckland, New Zealand
⁶ The First Hospital of China Medical University Hunnan Campus, Shenyang, Liaoning, China
⁷ Macquarie Medical School, Macquarie University, North Ryde, NSW, Australia
⁸ Icahn School of Medicine at Mount Sinai, New York, NY, USA
⁹ BeOne Medicines, Ltd, San Carlos, CA, USA
¹⁰ BeOne Medicines, Ltd, Beijing, China
¹¹ BeOne Medicines UK Ltd, London, UK
¹² =lc4ClcD L#s[ g(a|tpjtz ]nanEnamV |NPu1

HhH}/d

^^:[-h4h-,I^=-d7c-9I: